27 July 2020 – Gent, Belgium – Thuja portfolio company Indigo Diabetes concludes a €38 million financing round for a ground-breaking invisible diabetes sensor.
The new investment round was led by Fund+ and will enable Indigo Diabetes to prepare and run a pivotal clinical study. The small sensor chip is designed to be inserted underneath the skin and measure glucose and ketones in people with diabetes. The latter is a worldwide first and aims at enabling the faster detection of life-threatening situations by both the users and their healthcare providers. At the same time, the invisible sensor aims to substantially improve the quality of life of diabetics worldwide.
"Clinical evidence has proven that continuous glucose monitors are effective tools for people with diabetes to improve glycemic control. We strongly believe Indigo's invisible sensor is the next stage. Not only will it allow better monitoring and treatment of diabetes, but the psychological impact of continuously painful finger-pricking or having to live daily with visible sensors will be a thing of the past thanks to this Indigo sensor," says Dr Harrold van Barlingen of Thuja Capital.
Thuja capital was the lead investor of the 2016 series A round and has continued its support of Indigo by reinvesting in the current serie B capital round. In addition to this, Harrold van Barlingen will also continue his role a board member.
Please find the full press release here in Dutch and English.